細胞科学と治療のジャーナル
オープンアクセス

概要

Cardiovascular Complications During COVID-19 Infection

Aswathi Rajagopalan, Wilner Martinez lopez, Radha Saraswathy

In December 2019 a serious outbreak of pneumonia emerged in china. The infection Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2), spreads the infection rapidly from China to other countries, and the World Health Organization (WHO) announced Coronavirus disease 2019 (COVID-19) a pandemic. Corona Viruses (CoV) contain a single-stranded RNA genome. The Coronavirus infected through respiratory droplets will be a high-level of transmission and to develop acute respiratory failure but a large portion of patients exploit cardiovascular manifestations. The WHO has stated by august 2020 that 26,763,217confirmed COVID-19 positive cases and 876,616 deaths were determined all over the world. COVID-19 the consequential hazards to the public health care system of COVID-19 infection for people underlying medical problems have a significantly increased risk of death, especially the ones carrying hypertension, diabetes, cardiovascular diseases, and cerebrovascular disease. Possible vaccines and drugs to treat COVID-19 infection are undergoing. This review discussed cardiovascular complications in severe acute respiratory syndrome produced by Corona Virus-2 (SARS-CoV-2).